Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSF1 | Q00613 | 15/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arimoclomol SCHEMBL12254223 | 1.00 | HSF1 (0.54) | HSF1CYP2D6TSHRHIF1AATM | |
| Arimoclomol SCHEMBL12254225 | 1.00 | HSF1 (0.54) | HSF1CYP2D6TSHRHIF1AATM | |
| Arimoclomol SCHEMBL2324741 | 1.00 | HSF1 (0.54) | HSF1CYP2D6TSHRHIF1AATM | |
| Arimoclomol SCHEMBL1896428 | 1.00 | HSF1 (0.54) | HSF1CYP2D6TSHRHIF1AATM | |
| Arimoclomol SCHEMBL25257807 | 1.00 | HSF1 (0.54) | HSF1CYP2D6TSHRHIF1AATM | |
| Arimoclomol SCHEMBL5699241 | 1.00 | HSF1 (0.54) | HSF1CYP2D6TSHRHIF1AATM | |
| Arimoclomol SCHEMBL25258754 | 1.00 | HSF1 (0.54) | HSF1CYP2D6TSHRHIF1AATM | |
| Arimoclomol SCHEMBL5699253 | 0.99 | HSF1 (0.53) | HSF1CYP2D6TSHRHIF1AATM | |
| Arimoclomol SCHEMBL7052423 | 0.99 | HSF1 (0.53) | HSF1CYP2D6TSHRHIF1AATM | |
| Arimoclomol SCHEMBL5699251 | 0.99 | HSF1 (0.53) | HSF1CYP2D6TSHRHIF1AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097008-A1 | ACETYL LEUCINE FOR USE IN TREATING NIEMANN-PICK DISEASE TYPE C | INTRABIO INC. | 2026-04-09 | — | — | US | claimed |
| US-12576076-B2 | Use of HSP70 as a regulator of enzymatic activity | Zevra Denmark A/S (DK) | 2026-03-17 | — | — | US | claimed |
| EP-4702057-A1 | IN VIVO IMAGING OF AN ALS BIOMARKER AND MEANS THEREFOR | AL-S Pharma AG (CH) | 2026-03-04 | — | — | EP | claimed |
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | UNIV COLUMBIA (US) | 2025-12-18 | — | — | US | claimed |
| EP-4171559-B1 | ARIMOCLOMOL FOR TREATING GAUCHER DISEASE | ZEVRA DENMARK AS (DK) | 2025-09-10 | — | — | EP | claimed |
| EP-4608399-A1 | ARIMOCLOMOL COMPOSITIONS FOR USE IN TREATING NIEMANN PICK DISEASE TYPE C (NPC) | Zevra Denmark A/S (DK) | 2025-09-03 | — | — | EP | claimed |
| US-20250268748-A1 | TREATMENT OF SPINAL MUSCULAR ATROPHY BY INDUCING HEAT SHOCK RESPONSE | THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN’S HOSPITAL | 2025-08-28 | — | — | US | claimed |
| EP-3837011-B1 | TOFACITINIB FOR USE IN TREATING, DELAYING PROGRESSION OF OR REDUCING THE SEVERITY OF AMYOTROPHIC LATERAL SCLEROSIS | UNIV MICHIGAN REGENTS (US) | 2025-07-09 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2025088514-A1 | METTL3-METTL14-COMPLEX INHIBITORS FOR THE TREATMENT OF NEUROMUSCULAR DEGENERATIVE PATHOLOGIES CAUSED BY OR LINKED TO MUTATIONS IN THE FUS GENE | Università degli Studi di Roma “La Sapienza” (IT) | 2025-05-01 | — | — | WO | claimed |
| WO-2009035473-A2 | METHOD OF TREATING BINGE EATING DISORDER, OBESITY RESULTING FROM BINGE EATING BEHAVIOR AND DEPRESSIVE DISORDERS | SANFILIPPO LOUIS C (US) | 2009-03-19 | — | — | WO | claimed |
| WO-2008137149-A1 | DIABETIC WOUND HEALING | CYTRX CORPORATION (US) | 2008-11-13 | — | — | WO | claimed |
| WO-2008133884-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-11-06 | — | — | WO | claimed |
| WO-2008116165-A2 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY, INC. (US) | 2008-09-25 | — | — | WO | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2008070010-A2 | HYDROXYLAMINE DERIVATIVES FOR THE TREATMENT OF STROKE | CYTRX CORPORATION (US) | 2008-06-12 | — | — | WO | claimed |
| US-20080066741-A1 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | HUNTER, CHARLES ERIC | 2008-03-20 | — | — | US | claimed |
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576076-B2 | Use of HSP70 as a regulator of enzymatic activity | HSPB1, HSPA1B, HSPD1 | HSF1 22/4885CYP2D6 2631/4885TSHR 4461/4885 |
| US-20260097008-A1 | ACETYL LEUCINE FOR USE IN TREATING NIEMANN-PICK DISEASE TYPE C | NPC1, NPC1L1, NAA50 | HSF1 3863/4885CYP2D6 3272/4885TSHR 4247/4885 |
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | HSPA5, ATP2A1, DNAJC10 | HSF1 98/4885CYP2D6 3832/4885TSHR 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.